Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined PBM, PRP, and Exosomes in ASD
NCT06600529Recruiting
- Sponsor
- Iffat Anwar Medical Complex
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- Device-based Delivery, Lipid-based Nanoparticles, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Randomised, open-label trial of umbilical cord-derived exosomes and autologous platelet-rich plasma in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Iffat Anwar Medical Complex. Primary endpoint: Childhood Autism Rating Scale at 1 year. Started Aug 2024; status: recruiting.
02
Drugs
umbilical cord-derived exosomesautologous platelet-rich plasma
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06600529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600529.